Aptima Combo 2® (CT/NG) Assay

Protect Women’s Health by Screening for Chlamydia (CT) and Gonorrhea (NG)

~1 in 2

new STIs were acquired by people aged 15—24 years old.1

5.6M

new chlamydia and gonorrhea cases are estimated every year in the U.S.2

84%

of chlamydia and gonorrhea infections
are asymptomatic.3

Untreated Infections Can Lead to Long-term Health Issues

women each year become infertile due to undiagnosed STIs4

Ovaries Infographic

%

As many as 30% of untreated chlamydia infections progress to Pelvic Inflammatory Disease (PID).5

%

A study estimated that 45% of tubal factor infertility cases were caused by chlamydia infections.6

Ovaries Infographic

Improving Patient Care Through Established Screening Guidelines

Major public health and medical societies are all aligned in their recommended screening for sexually active women under 25 years of age.7-11

  • Screening implementation still faces multiple barriers such as lack of access, lack of awareness, and confidentiality concerns.
  • Only 59% of sexually active women ages 16–20 are screened for chlamydia per guidelines.12
CDC Logo

CDC

Centers for Disease Control and Prevention

ACOG Logo

ACOG

American College of Obstetrics and Gynecology

AAPPNG Logo

AAP

American Academy of Pediatrics

U.S Preventive Services

USPSTF

U.S. Preventive Services Task Force

AAFP_Logo

AAFP

American Academy of Family Physicians

The CDC recommends that providers might consider opt-out screening for adolescent and young adult females to increase screening, be cost-saving, and identify infections among patients who do not disclose sexual behavior.7

Elevate Patient Care by Identifying Undiagnosed Infections with Universal Screening13

Introducing a Universal Screening protocol may help prevent risk of infertility due to undiagnosed infections, while also helping to decrease STI prevalence and reduce total cost to patients and healthcare organizations.

Total Cost chart
Chlamydia Prevalance chart
Aptima Multiswab

Support Universal Screening with the Aptima® Multitest Swab

Introducing this protocol is easy, starting with the way you collect a sample. Detect up to 7 infections and disease states from just one vaginal swab sample with the Aptima® Multitest Swab.14

Learn More

Get More Results From One Sample

Giving physicians trusted results to help protect patients from long-term consequences.

Testing may also be performed with any of the following alternative specimen types:

  • Urine sample
  • Female endocervical swab
  • Liquid-based cytology specimens
  • Urine sample
  • Female endocervical swab
  • Liquid-based cytology specimens
  • Male urethal swab
  • Rectal and oropharyngeal swab
  • Male urethal swab
  • Rectal and oropharyngeal swab
Specimen Type Aptima Combo 2® Assay (CT/NG)15
Chlamydia Gonorrhea
Sensitivity Specificity Sensitivity Specificity
ThinPrep Test

ThinPrep® Test Vial

 98.2% 100% 100% 100%
Multitest Swab

Multitest Swab

Clinician Collected Vaginal Sample

 97.2% 98.5% 97.7% 99.6%

Multitest Swab

Patient Collected Vaginal Sample

 97.2% 98.5% 97.7% 99.6%

Multitest Swab

Clinician Collected Throat
Swab Sample

 88.2% 99.7% 96.1% 98.9%

Multitest Swab

Clinician Collected Rectal
Swab Sample

 91.6%† 98.9%† 97.5%† 99.5%†
Unisex Collection

Female Endocervical Swab

Clinician Collected Endocervical

 97.2% 99.3% 100% 99.8%

Male Urethral Swab

Clinician Collected Male Urethral

 100% 99.1% 100% 100%
Urine Collection

Aptima® Urine

(Female Sample)

 PPA
98.9%		 NPA
99.8%		 PPA
96.6%		 NPA
100%

Aptima® Urine

(Male Sample)

 95.2% 99.8% 98.7% 99.7%
†Equivocal results excluded. Refer to the package insert for more information.

Specimen Type

Aptima Combo 2® Assay
(CT/NG)15

ThinPrep® Vial Test
Chlamydia Gonorrhea
Sensitivity Specificity Sensitivity Specificity
98.2% 100% 100% 100%
Multitest Swab - Vaginal
Chlamydia Gonorrhea
Sensitivity Specificity Sensitivity Specificity
97.2% 98.5% 97.7% 99.6%
Multitest Swab - Throat
Chlamydia Gonorrhea
Sensitivity Specificity Sensitivity Specificity
88.2% 99.7% 96.1% 98.9%
Multitest Swab - Rectal
Chlamydia Gonorrhea
Sensitivity Specificity Sensitivity Specificity
91.6%† 98.9%† 97.5%† 99.5%†
Female Endocervial Swab
Chlamydia Gonorrhea
Sensitivity Specificity Sensitivity Specificity
97.2% 99.3% 100% 99.8%
Male Urethral Swab
Chlamydia Gonorrhea
Sensitivity Specificity Sensitivity Specificity
100% 99.1% 100% 100%
Aptima® Urine - Female
Chlamydia Gonorrhea
Sensitivity Specificity Sensitivity Specificity
PPA
98.9%		 NPA
99.8%		 PPA
96.6%		 NPA
100%
Aptima® Urine - Male
Chlamydia Gonorrhea
Sensitivity Specificity Sensitivity Specificity
95.2% 99.8% 98.7% 99.7%
†Equivocal results excluded. Refer to the package insert for more information.

Let’s Connect

Have a question or need to talk to a Hologic team member? We’re here to help.

Contact Us
References

†Equivocal results excluded. Refer to the package insert for more information.

1. Kreisel, et al. Sexually Transmitted Infections Among US Women and Men: Prevalence and Incidence Estimates, 2018, Sexually Transmitted Diseases: April 2021-Volume 48-Issue 4-p 208-214 doi: 10.1097/OLQ.0000000000001355.

2. CDC. Sexually transmitted infections prevalence, incidence, and cost estimates in the united states. Sexually Transmitted Infections (STIs). Published 2024. Accessed February 18, 2026. https://www.cdc.gov/sti/php/communication-resources/prevalence-incidence-and-cost-estimates.html

3. Detels R, Green AM, Klausner JD, et al. The incidence and correlates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries. Sex Transm Dis. 2011;38(6):503-509.

4. Sexually Transmitted Infections among Young Americans | National Prevention Information Network | Connecting public health professionals with trusted information and each other. npin.cdc.gov. Published 2016. Accessed February 18, 2026. https://npin.cdc.gov/publication/sexually-transmitted-infections-among-young-americans

5. Swain GR, et al. Decision analysis: point-of-care Chlamydia testing vs. laboratory-based methods. Clin Med Res. 2004;2(1):29-35. doi:10.3121/ cmr.2.1.29.

6. Price MJ, et al. How Much Tubal Factor Infertility is Caused by Chlamydia? Estimates Based on Serological Evidence Corrected for Sensitivity and Specificity. Sex Transm Dis. 2012;39(3):608-613. doi:0.1097/OLQ.0b013e3182572475.

7. CDC. Morbidity and Mortality Weekly Report Sexually Transmitted Infections Treatment Guidelines, 2021 Centers for Disease Control and Prevention MMWR Editorial and Production Staff (Serials) MMWR Editorial Board.; 2021. Accessed February 18, 2026. https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf

8. Yonke N, Aragon M, Phillips JK. Chlamydial and Gonococcal Infections: Screening, Diagnosis, and Treatment. Am Fam Physician. 2022;105(4):388-396

9. Chlamydia, Gonorrhea, and Syphilis. www.acog.org. Published April 2024. Accessed February 18, 2026. https://www.acog.org/womens-health/faqs/chlamydia-gonorrhea-and-syphilis

10. US Preventive Services Task Force. Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(10):949–956. doi:10.1001/jama.2021.14081

11. Screening for Nonviral Sexually Transmitted Infections in Adolescents and Young Adults. PEDIATRICS. 2014;134(1):e302-e311. doi:https://doi.org/10.1542/peds.2014-1024

12. U.S. Department of Health and Human Services. 2020. Sexually Transmitted Infections National Strategic Plan for the United States: 2021–2025. Washington, DC.

13. Owusu-Edusei K, et al. Cost- Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the U.S. Am J Prev Med. 2016;51(2):216-24. doi:10.1016/j.amepre.2016.01.007

14. Aptima Multitest Swab. US package insert AW-26253-001. Hologic, Inc.; 2022.

15. Aptima Combo 2 Assay. US package insert AW-25929-001. Hologic, Inc.; 2023.